Ratings by Leerink (Roanna Ruiz)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/7/2026 | Akebia Therapeutics | AKBA | Downgrade | Market Perform (Outperform) |
0.95 (0.59) |
-37.89% | Details | |
| 7/13/2026 | Kardigan Inc | KARD | New Coverage | Outperform (N/A) |
24.64 (12.85) |
-47.85% | Details | |
| 4/21/2026 | Trevi Therapeutics | TRVI | Maintain | Outperform (N/A) |
|
Details | ||
| 4/14/2026 | Akebia Therapeutics | AKBA | Maintain | Outperform (N/A) |
|
Details | ||
| 4/13/2026 | MannKind | MNKD | Maintain | Outperform (N/A) |
|
Details | ||
| 3/26/2026 | iBio, Inc. | IBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 3/12/2026 | Ardelyx, Inc | ARDX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/10/2026 | Cytokinetics | CYTK | Maintain | Outperform (N/A) |
|
Details | ||
| 3/10/2026 | ARS Pharmaceuticals Inc | SPRY | Maintain | Outperform (N/A) |
|
Details | ||
| 3/6/2026 | CorMedix | CRMD | Maintain | Outperform (N/A) |
|
Details | ||
| 3/2/2026 | United Therapeutics Corp. | UTHR | Maintain | Outperform (N/A) |
|
Details | ||
| 2/26/2026 | Vir Biotechnology | VIR | Maintain | Outperform (N/A) |
|
Details | ||
| 2/2/2026 | Trevi Therapeutics | TRVI | Maintain | Outperform (N/A) |
|
Details | ||
| 1/12/2026 | CorMedix | CRMD | Maintain | Outperform (N/A) |
|
Details | ||
| 1/6/2026 | NewAmsterdam Pharma Co NV | NAMS | Maintain | Outperform (N/A) |
|
Details | ||
| 12/9/2025 | MannKind | MNKD | Maintain | Outperform (N/A) |
|
Details | ||
| 12/9/2025 | Vir Biotechnology | VIR | Maintain | Outperform (N/A) |
|
Details | ||
| 11/19/2025 | Trevi Therapeutics | TRVI | Maintain | Outperform (N/A) |
|
Details | ||
| 11/13/2025 | Trevi Therapeutics | TRVI | New Coverage | Outperform (N/A) |
11.85 (12.77) |
7.76% | Details | |
| 11/13/2025 | Contineum Therapeutics | CTNM | New Coverage | Outperform (N/A) |
11.47 (8.35) |
-27.2% | Details | |
| 11/13/2025 | MannKind | MNKD | New Coverage | Outperform (N/A) |
5.25 (3.05) |
-41.9% | Details | |
| 11/6/2025 | NewAmsterdam Pharma Co NV | NAMS | Maintain | Outperform (N/A) |
|
Details | ||
| 10/30/2025 | Amarin Corporation | AMRN | Maintain | Market Perform (N/A) |
|
Details | ||
| 10/17/2025 | iBio, Inc. | IBIO | New Coverage | Outperform (N/A) |
0.85 (0.84) |
-1.18% | Details | |
| 9/30/2025 | Enanta Pharmaceuticals | ENTA | Maintain | Market Perform (N/A) |
|
Details | ||
| 9/23/2025 | CorMedix | CRMD | Maintain | Outperform (N/A) |
|
Details | ||
| 8/19/2025 | Xeris Pharmaceuticals | XERS | Maintain | Outperform (N/A) |
|
Details | ||
| 6/5/2025 | Xeris Pharmaceuticals | XERS | Maintain | Outperform (N/A) |
|
Details | ||
| 6/4/2025 | United Therapeutics Corp. | UTHR | Maintain | Outperform (N/A) |
|
Details | ||
| 4/28/2025 | Akebia Therapeutics | AKBA | New Coverage | Outperform (N/A) |
2.38 (0.95) |
-60.08% | Details | |
| 3/7/2025 | CorMedix | CRMD | New Coverage | Outperform (N/A) |
9.49 (7.79) |
-17.91% | Details | |
| 3/5/2025 | Lexicon Pharmaceuticals | LXRX | Downgrade | Market Perform (Outperform) |
0.29 (1.56) |
437.93% | Details | |
| 3/3/2025 | Aquestive Therapeutics | AQST | Maintain | Outperform (N/A) |
|
Details | ||
| 2/19/2025 | Aquestive Therapeutics | AQST | Maintain | Outperform (N/A) |
|
Details | ||
| 11/26/2024 | Enanta Pharmaceuticals | ENTA | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/20/2024 | NewAmsterdam Pharma Co NV | NAMS | Maintain | Outperform (N/A) |
|
Details | ||
| 11/1/2024 | Lexicon Pharmaceuticals | LXRX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/25/2024 | Aquestive Therapeutics | AQST | Maintain | Outperform (N/A) |
|
Details | ||
| 10/18/2024 | Lexicon Pharmaceuticals | LXRX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/10/2024 | Aquestive Therapeutics | AQST | New Coverage | Outperform (N/A) |
3.29 (4.08) |
24.01% | Details | |
| 4/5/2024 | Ardelyx, Inc | ARDX | New Coverage | Outperform (N/A) |
7.16 (3.13) |
-56.28% | Details | |
| 3/5/2024 | ARS Pharmaceuticals Inc | SPRY | Upgrade | Outperform (Market Perform) |
8.65 (4.18) |
-51.68% | Details | |
| 2/5/2024 | United Therapeutics Corp. | UTHR | New Coverage | Outperform (N/A) |
213.41 (563.49) |
164.04% | Details | |
| 1/5/2024 | Vir Biotechnology | VIR | Maintain | Outperform (N/A) |
|
Details | ||
| 9/21/2023 | ARS Pharmaceuticals Inc | SPRY | Downgrade | Market Perform (Outperform) |
2.92 (4.18) |
43.15% | Details | |
| 8/15/2023 | Cytokinetics | CYTK | New Coverage | Outperform (N/A) |
32.10 (62.86) |
95.83% | Details | |
| 4/11/2023 | Corcept Therapeutics | CORT | New Coverage | Market Perform (N/A) |
22.63 (116.28) |
413.83% | Details | |
| 4/4/2023 | Pardes Biosciences | PRDS | Downgrade | Market Perform (Outperform) |
1.32 (2.16) |
63.64% | Details | |
| 12/20/2022 | NewAmsterdam Pharma Co NV | NAMS | New Coverage | Outperform (N/A) |
11.31 (21.49) |
90.01% | Details | |
| 10/24/2022 | Myovant Sciences Ltd. | MYOV | Downgrade | Market Perform (Outperform) |
24.54 (26.98) |
9.94% | Details | |
| 10/11/2022 | scPharmaceuticals | SCPH | Upgrade | Outperform (Market Perform) |
4.02 (5.67) |
41.04% | Details | |
| 9/14/2022 | Vir Biotechnology | VIR | New Coverage | Outperform (N/A) |
20.57 (10.57) |
-48.61% | Details | |
| 8/9/2022 | Myovant Sciences Ltd. | MYOV | Upgrade | Outperform (Market Perform) |
15.67 (26.98) |
72.18% | Details | |
| 7/14/2022 | ContraFect Corp. | CFRX | Downgrade | Market Perform (Outperform) |
2.85 (0.23) |
-91.93% | Details | |
| 5/19/2022 | Enanta Pharmaceuticals | ENTA | Maintain | Market Perform (N/A) |
|
Details | ||
| 5/5/2022 | Aligos Therapeutics Inc. | ALGS | Downgrade | Market Perform (Outperform) |
1.24 (4.96) |
300% | Details | |
| 5/5/2022 | Amarin Corporation | AMRN | Downgrade | Market Perform (Outperform) |
1.56 (11.51) |
637.82% | Details | |
| 3/15/2022 | Pardes Biosciences | PRDS | New Coverage | Outperform (N/A) |
5.64 (2.16) |
-61.7% | Details | |
| 3/11/2022 | Aligos Therapeutics Inc. | ALGS | Maintain | Outperform (N/A) |
|
Details | ||
| 1/31/2022 | Amarin Corporation | AMRN | Maintain | Outperform (N/A) |
|
Details | ||
| 12/31/2021 | Xeris Pharmaceuticals | XERS | Maintain | Outperform (N/A) |
|
Details | ||
| 11/18/2021 | Atea Pharmaceuticals | AVIR | Downgrade | Market Perform (Outperform) |
8.69 (4.08) |
-53.05% | Details | |
| 11/17/2021 | Xeris Pharmaceuticals | XERS | New Coverage | Outperform (N/A) |
2.39 (10.79) |
351.46% | Details | |
| 9/9/2021 | Atea Pharmaceuticals | AVIR | New Coverage | Outperform (N/A) |
27.70 (4.08) |
-85.27% | Details | |
| 9/9/2021 | Amarin Corporation | AMRN | New Coverage | Outperform (N/A) |
5.15 (11.51) |
123.5% | Details | |
| 9/9/2021 | Myovant Sciences Ltd. | MYOV | New Coverage | Market Perform (N/A) |
25.81 (26.98) |
4.53% | Details | |
| 9/9/2021 | Aligos Therapeutics Inc. | ALGS | New Coverage | Outperform (N/A) |
15.31 (4.96) |
-67.6% | Details | |
| 9/9/2021 | ContraFect Corp. | CFRX | New Coverage | Outperform (N/A) |
3.90 (0.23) |
-94.1% | Details | |
| 9/9/2021 | Enanta Pharmaceuticals | ENTA | New Coverage | Market Perform (N/A) |
57.17 (11.31) |
-80.22% | Details | |
| 9/9/2021 | scPharmaceuticals | SCPH | New Coverage | Market Perform (N/A) |
5.95 (4.02) |
-32.44% | Details |
